[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100216108":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":10,"locations":27,"responsibleParty":40,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"LEO Pharma","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"all eligible patients",null,"Treatment with Picato according to Summary of Product Characteristics (SmPC)",[13],"Drug: Ingenol Mebutate",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Ingenol Mebutate","No intervention: observation of routine use of Picato®",[9],[21],"Picato®",[23],{"name":24,"affiliation":25,"role":26},"Thomas Diepgen, Prof. Dr. med.","University Hospital Heidelberg","PRINCIPAL_INVESTIGATOR",[28],{"facility":29,"status":10,"city":30,"state":10,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":10},"Universitätsklinikum Heidelberg\u002FKlinische Sozialmedizin","Heidelberg","D-69115","Germany","DE",{"type":35,"coordinates":36},"Point",[37,38],8.69079,49.40768,{"lat":38,"lon":37},{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100216108","assessment-of-treatment-success-and-quality-of-life-in-patients-with-actinic-keratoses-under-therapy-with-ingenol-mebutate-in-a-period-of-8-weeks-100216108",false,"NCT02090465","Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks","Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate (Picato) in a Period of 8 Weeks.","Inclusion Criteria:\n\n• Non-hyperkeratotic, non-hypertrophic actinic keratoses where treatment with Picato® is indicated and the treatment is intended by physicians.\n\nExclusion Criteria:\n\n* Preceding use of Picato® on the area planned for treatment\n* Any other specific local treatment of actinic keratoses on the area planned for treatment during the last 8 weeks\n* Melanoma, squamous cell carcinoma or spinalioma on the area planned for treatment\n* Open wounds on the area planned for treatment\n* Contraindications according to prescribing information","ALL","18 Years",{"count":52,"type":53},840,"ACTUAL","OBSERVATIONAL","Assessment of treatment success and quality of life in patients with actinic keratoses under therapy with Ingenol Mebutate (Picato) in a period of 8 weeks.",[57],"Actinic Keratosis",[57],"COMPLETED","2019-12-13",{"date":62,"type":53},"2019-12-17",{"date":64,"type":53},"2013-07",{"date":66,"type":53},"2013-12",{"name":5,"class":6},1]